Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Immunoglobulin G (IgG), administered as Intravenous Immunoglobulin (IVIG), has been investigated as a treatment for Multiple Sclerosis (MS), especially in relapsing-remitting forms and in special circumstances such as during pregnancy or when other therapies are contraindicated. The rationale behind IVIG use is its immunomodulatory effects, including neutralization of pathogenic autoantibodies, modulation of the complement system, and alteration of cytokine profiles. Early small studies and case series in the 1990s and early 2000s suggested some benefit in reducing relapse rates and disease progression, particularly when standard therapies could not be used.

However, subsequent larger randomized controlled trials and systematic reviews have shown only modest or inconsistent benefit, and IVIG is not currently considered a first-line therapy for MS. The 2012 Cochrane review concluded that IVIG might reduce relapse rates in relapsing-remitting MS, but the effect was small and the quality of evidence was low to moderate. Major clinical guidelines (e.g., AAN, ECTRIMS) do not recommend IVIG as routine MS treatment, though it may be considered in specific situations (e.g., pregnant women not candidates for other therapies).

In summary, there is scientific investigation and some limited evidence for IVIG/IgG use in MS, but the overall strength of evidence is weak (rated 2/5), and it is not a standard treatment.

More about Immunoglobulin G
More about Multiple Sclerosis

Other ingredients used for Multiple Sclerosis

Other health conditions supported by Immunoglobulin G

Products containing Immunoglobulin G